UMs are larger and more posterior in males

Article

Uveal melanomas (UMs) are more likely to be larger and more posterior in male patients

Uveal melanomas (UMs) are more likely to be larger and more posterior in male patients, compared to female patients, revealed a study in the journal Eye.

Dr B.E. Damato et al., Ocular Oncology Service, Royal Liverpool University Hospital, Liverpool, UK, reviewed records from the Liverpool Ocular Oncology Centre (LOOC) database between 1993 and 2010. The χ2 test was used to identify categorical variables between male and female patients and the Mann-Whitney test was used to compare continuous variables.

Of the 3380 patients included in the study, 1685 were women and 1695 were men. Tumours developed in the choroid in 89.5% of the patients, 5.3% in the ciliary body and 5.2% in the iris.

In female patients the tumours were less likely to originate in the choroid and demonstrated a more circumferential spread in the ciliary body. But tumours in the male patients were more likely to develop within 3 mm of the optic disc or fovea.

The median diameters of the largest basal tumour in male patients were 12.2 mm and 11.9 mm in men and women, respectively. The median tumour thicknesses were 4.4 mm and 3.8 mm for men and women, respectively.

Prevalence of extraocular spread was higher in women with 112 suffering from ciliary body tumours, compared to 68 in the male patients. Of the 175 iris melanomas discovered, 103 were found in the female patients.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.